CytomX Therapeutics, Inc. News Releases http://ir.cytomx.com/ CytomX Therapeutics, Inc. News Releases en CytomX Therapeutics Provides Update on Anti-PD-L1 Probody CX-072 at 2019 ASCO Annual Meeting http://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-provides-update-anti-pd-l1-probody-cx-072 - Monotherapy Expansion Cohorts Show Clinical Activity Across Multiple Cancer Types - - Differentiated Safety Profile Continues to Emerge - SOUTH SAN FRANCISCO, Calif. , June 01, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical Sat, 01 Jun 2019 09:00:00 -0400 CytomX Therapeutics, Inc. News Releases 9126 CytomX Therapeutics to Present at Upcoming Healthcare Conferences http://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-present-upcoming-healthcare-conferences SOUTH SAN FRANCISCO, Calif. , May 28, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, announced Tue, 28 May 2019 08:00:00 -0400 CytomX Therapeutics, Inc. News Releases 9101 CytomX Therapeutics Announces Presentations at 2019 ASCO Annual Meeting http://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-announces-presentations-2019-asco-annual SOUTH SAN FRANCISCO, Calif. , May 15, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced Wed, 15 May 2019 17:20:00 -0400 CytomX Therapeutics, Inc. News Releases 9091 CytomX Therapeutics Announces First Quarter 2019 Financial Results http://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-announces-first-quarter-2019-financial Company to Host a Conference Call Today, May 9, 2019, at 5:00 p.m. EDT / 2:00 p.m. PDT SOUTH SAN FRANCISCO, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational Thu, 09 May 2019 16:10:00 -0400 CytomX Therapeutics, Inc. News Releases 9051 CytomX Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference http://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-present-bank-america-merrill-lynch-2019 SOUTH SAN FRANCISCO, Calif. , May 07, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, announced Tue, 07 May 2019 08:00:00 -0400 CytomX Therapeutics, Inc. News Releases 9041 CytomX Therapeutics to Announce First Quarter 2019 Financial Results http://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-announce-first-quarter-2019-financial -Teleconference Scheduled for May 9, 2019, at 5:00 p.m. ET- SOUTH SAN FRANCISCO, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on Thu, 02 May 2019 08:00:00 -0400 CytomX Therapeutics, Inc. News Releases 9026 CytomX Therapeutics Appoints Elaine V. Jones, Ph.D., to Board of Directors http://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-appoints-elaine-v-jones-phd-board-directors SOUTH SAN FRANCISCO, Calif. , April 22, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today Mon, 22 Apr 2019 16:05:00 -0400 CytomX Therapeutics, Inc. News Releases 8991 AACR 2019 Presentations Highlight CX-2009, a First-In-Class Probody Drug Conjugate Targeting Novel Tumor Antigen, CD166 http://ir.cytomx.com/news-releases/news-release-details/aacr-2019-presentations-highlight-cx-2009-first-class-probody - PROCLAIM-CX-2009 Dose Escalation Study Demonstrates Anti-Tumor Activity in Multiple Tumor Types - - Preclinical Studies Suggest Role of CD166 Expression Level in Anti-Cancer Activity and Potential for Combination of CX-2009 with Immunotherapy - SOUTH SAN FRANCISCO, Calif. Tue, 02 Apr 2019 08:00:00 -0400 CytomX Therapeutics, Inc. News Releases 8966 CytomX Therapeutics Announces Transition of Chief Financial Officer http://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-announces-transition-chief-financial-officer SOUTH SAN FRANCISCO, Calif. , March 25, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today Mon, 25 Mar 2019 16:05:00 -0400 CytomX Therapeutics, Inc. News Releases 8956 CytomX to Present at Upcoming Healthcare Conferences http://ir.cytomx.com/news-releases/news-release-details/cytomx-present-upcoming-healthcare-conferences-0 SOUTH SAN FRANCISCO, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, announced Tue, 05 Mar 2019 16:05:00 -0500 CytomX Therapeutics, Inc. News Releases 8931